Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
ICON helps drug companies test new medicines in people and handles the paperwork to get them approved.
ICON plc runs clinical trials for the drug and medical device industry. When a company like Pfizer or a small biotech has a promising molecule, it can't just sell it — regulators demand proof that it works and is safe in real patients. That proof comes from trials: recruiting hundreds or thousands of people, dosing them, tracking every side effect, and compiling the results into a submission that a regulator will accept. ICON does that work for a fee. It finds the patients, runs the sites, manages the data, and handles the regulatory filings. Think of it as the outsourced engine room of the pharmaceutical industry — the drugmaker owns the ship, but ICON keeps the boilers running.
The business has two main parts. The bigger one is clinical research, which covers running and monitoring trials across every phase, from tiny early safety studies to huge late-stage tests with tens of thousands of patients. That's roughly the large majority of revenue. The second is a set of adjacent lab and consulting services: central lab testing, where blood and tissue samples from trial sites around the world get analyzed in one place so the results are consistent, plus data analytics and real-world evidence work. Customers are almost entirely pharmaceutical, biotech, and medical device companies, and the top handful of giant drugmakers account for a big slice of sales. They choose ICON because trials are expensive and slow, and a specialist that runs them constantly can do it faster and cheaper than building the capability in-house.
ICON is Irish by headquarters but American in market — it has been listed on Nasdaq for years. The company grew largely by buying scale, with the biggest turning point being the 2021 acquisition of PRA Health Sciences, which roughly doubled its size and made it one of the two or three largest trial operators in the world. Recent years have been choppy: after a boom in trial activity during the pandemic, biotech funding tightened and big drugmakers trimmed their pipelines, which slowed new bookings and weighed on growth. ICON generates real cash from this work, and it uses that cash to pay down the debt taken on for PRA, fund small bolt-on deals, and buy back shares. The bet long term is simple: more medicines are coming, more of them are biologics and personalized treatments that are complicated to test, and drugmakers would rather hand that complexity to a specialist than staff up for it themselves.
Saved answer · last researched 10 Oct 2026